

November 15, 2018

To: All Concerned Parties

Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Mothers Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8049

SP-01 Sancuso® First Delivery

Tokyo, Japan, November 15th, 2018—Solasia Pharma K.K. (TSE:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, officially announced today that Solasia has made its first delivery of SP-01 Sancuso® (the Transdermal Patch for the Prevention of CINV) to Itochu Corporation which will be commercialized in China.

Following this delivery, SP-01 Sancuso® will be launched in China in 1Q 2019. Solasia will commercialize using its own sales force in Beijing, Shanghai, and Guangzhou. As for the rest of China, SP-01 Sancuso® will be commercialized by Lee’s Pharmaceutical (HK) Limited.

With this delivery, Solasia will be booking its first product sales regarding SP-01 Sancuso®. Thus, the impact of this event is immaterial to the current fiscal year’s financial forecast, and no change in financial forecast will be announced as of now.

Disclaimer:

The forward-looking statements, including earnings forecasts, contained in this press release are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Such statements should not be construed as representing commitments on the part of the Company. Please be aware that actual performance may differ for a variety of reasons. Major factors affecting the Company’s actual performance include the economic conditions in which it operates, exchange rate fluctuations, the competitive situation and other factors. Information contained in this press release with regard to pharmaceuticals and medical devices (including products under development) is not provided for the purposes of advertising or medical advice.